Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC: pembrolizumab plus doxorubicin in advanced, recurrent, or metastatic endometrial cancer
2017-002824-26Phase 2Completed
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jan 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and doxorubicin in endometrial cancer (EC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Progression-free survival rate at 6 months. Started Jan 2018; status: completed.
02
Drugs
pembrolizumabdoxorubicin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2017-002824-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002824-26.